LUCIOSIM 80

Ask For Price

Brand name : LUCIOSIM 80
Key ingredient: Osimertinib 80 mg
Strength: 80 mg
Manufacturer: Lucius pharma
Pack: 30 tablets in one pack

Category:
single product banner

Ask For Price


Please prove you are human by selecting the Cup.

Bulk Order

Please prove you are human by selecting the Plane.

Description

Uses

LUCIOSIM 80 mg tablets are used in treating non-small cell lung cancers and in cancers that are EGFR mutation positive. It blocks the action of abnormal proteins that signal the cancer cells to multiply. In this way, LUCIOSIM 80 helps to stop the growth and spread of cancer in body.

Common side effects of LUCIOSIM 80 include:

  • Loose motions
  • Ulceration and swelling in mouth
  • Reduced appetite and weight
  • Decrease in blood cell counts
  • Dryness of skin
  • Dizziness
  • Vision changes
  • Low sodium
  • High Magnesium levels in blood

Warnings

You must always inform your doctor/pharmacist about your past and present drug allergies or other allergies before taking this medication. Drug allergies to both active ingredients and inactive agents are common.

Before using LUCIOSIM 80, inform your doctor or pharmacist regarding relevant medical history, especially that related to bleeding tendency, heart diseases, lung and liver ailments.

Not for pregnant and breastfeeding women.

Notes

Above information is meant for: Wholesalers, Suppliers, Doctors, Hospitals, Clinics, Resellers, Buying Houses, Medical Institutions and Pharmacies.

Medical Disclaimer

The information provided on this website pertaining to the ingredients, health related information, product description and treatment has been accumulated from several trustworthy sources. However, this information is not intended to replace of substitute any qualified doctor’s advice. The customers are requested to consult with their family physician before buying any of the medicines on the website. The given information is meant for resellers, buying houses, doctors, suppliers, hospitals, clinics, pharmacies and medical institute